Onl Therapeutics Closes First Tranche Of $15 Million Series C Financing To Advance Lead Compound Into Phase 2 Clinical Trial
Amount Raised
$15 Million
Round Type
Series C
Ann ArborBiotechnologyHealth CareBiopharmaDescription
ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on the first tranche of a $15 million Series C Preferred Stock financing round. Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).
Quick answer
ONL Therapeutics raised $15 Million in a Series C round, dated March 8, 2023. ONL Therapeutics is based in Ann Arbor, Michigan, United States.
- How much did ONL Therapeutics raise?
- ONL Therapeutics raised $15 Million in a Series C round on March 8, 2023.
- What does ONL Therapeutics do?
- ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease.
- Where is ONL Therapeutics based and how big is it?
- ONL Therapeutics is based in Ann Arbor, Michigan, United States. Fundz records about 10 employees.
- Who are the decision-makers at ONL Therapeutics?
- Fundz holds 1 contact at ONL Therapeutics, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biopharma and Biotechnology around the same time
Companies in the same sectors as ONL Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- DiaMedica Therapeutics raised $750K (Seed) on April 10, 2023.
- Milestone Pharmaceuticals raised $125M on March 28, 2023.
- Disc raised $63M (Funding Round) on February 14, 2023.
- Provention Bio raised $35M on February 13, 2023.
- CUREMARK LLC raised $1.3M (Seed) on January 30, 2023.
- Hasten Biopharmaceutic Ltd raised $315M (Funding Round) on April 20, 2023.
Who to call at ONL Therapeutics, and when
A new round usually means ONL Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ONL Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ONL Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ONL Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ONL Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
ONL Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.